Lobo C, Araujo A, Antunes A, Silva Pinto A, Godinho A, Pires C
Hematol Transfus Cell Ther. 2024; 46(1):67-71.
PMID: 38326179
PMC: 10935471.
DOI: 10.1016/j.htct.2024.01.001.
Adigwe O, Onoja S, Onavbavba G
J Blood Med. 2023; 14:367-376.
PMID: 37284610
PMC: 10239624.
DOI: 10.2147/JBM.S406196.
Isa H, Nnebe-Agumadu U, Nwegbu M, Okocha E, Chianumba R, Brown B
PLoS One. 2022; 17(11):e0276639.
PMID: 36355850
PMC: 9682971.
DOI: 10.1371/journal.pone.0276639.
Askew M, Smaldone A, Gold M, Smith-Whitley K, Strouse J, Jin Z
Pediatr Blood Cancer. 2022; 69(10):e29877.
PMID: 35856776
PMC: 9623811.
DOI: 10.1002/pbc.29877.
Ofakunrin A, Okpe E, Afolaranmi T, Olaosebikan R, Kanhu P, Adekola K
Afr Health Sci. 2021; 21(2):765-774.
PMID: 34795734
PMC: 8568227.
DOI: 10.4314/ahs.v21i2.36.
Perception to hydroxyurea therapy in patients with sickle cell disease: Report from 3 centers.
Korubo K, Onodingene N, Okoye H, Omunakwe H
Ann Afr Med. 2021; 20(2):127-131.
PMID: 34213480
PMC: 8378460.
DOI: 10.4103/aam.aam_36_20.
Smartphone-based sickle cell disease detection and monitoring for point-of-care settings.
Ilyas S, Sher M, Du E, Asghar W
Biosens Bioelectron. 2020; 165:112417.
PMID: 32729535
PMC: 7484220.
DOI: 10.1016/j.bios.2020.112417.
Current Issues and Options for Hormonal Contraception in Adolescents and Young Adult Women With Sickle Cell Disease: An Update for Health Care Professionals.
De Sanctis V, Soliman A, Daar S, Canatan D, Di Maio S, Kattamis C
Mediterr J Hematol Infect Dis. 2020; 12(1):e2020032.
PMID: 32395221
PMC: 7202337.
DOI: 10.4084/MJHID.2020.032.
Effectiveness and Safety of Hydroxyurea in the Treatment of Sickle Cell Anaemia Children in Jos, North Central Nigeria.
Ofakunrin A, Oguche S, Adekola K, Okpe E, Afolaranmi T, Diaku-Akinwumi I
J Trop Pediatr. 2019; 66(3):290-298.
PMID: 31608959
PMC: 7249733.
DOI: 10.1093/tropej/fmz070.
Associations of transcranial doppler velocity, age, and gender with cognitive function in children with sickle cell anemia in Nigeria.
Prussien K, Salihu A, Abdullahi S, Galadanci N, Bulama K, Belonwu R
Child Neuropsychol. 2018; 25(6):705-720.
PMID: 30269648
PMC: 6545195.
DOI: 10.1080/09297049.2018.1526272.
Combined hydroxyurea and ET receptor blockade reduces renal injury in the humanized sickle cell mouse.
Taylor C, Kasztan M, Tao B, Pollock J, Pollock D
Acta Physiol (Oxf). 2018; 225(2):e13178.
PMID: 30144292
PMC: 6936325.
DOI: 10.1111/apha.13178.
Skeletal and myocardial microvascular blood flow in hydroxycarbamide-treated patients with sickle cell disease.
Sachdev V, Sidenko S, Wu M, Minniti C, Hannoush H, Brenneman C
Br J Haematol. 2017; 179(4):648-656.
PMID: 28880374
PMC: 5696022.
DOI: 10.1111/bjh.14918.
Hydroxycarbamine: from an Old Drug Used in Malignant Hemopathies to a Current Standard in Sickle Cell Disease.
Cannas G, Poutrel S, Thomas X
Mediterr J Hematol Infect Dis. 2017; 9(1):e2017015.
PMID: 28293403
PMC: 5333733.
DOI: 10.4084/MJHID.2017.015.
Potential of Three Ethnomedicinal Plants as Antisickling Agents.
Nurain I, Bewaji C, Johnson J, Davenport R, Zhang Y
Mol Pharm. 2017; 14(1):172-182.
PMID: 28043127
PMC: 5963525.
DOI: 10.1021/acs.molpharmaceut.6b00767.
Emerging point-of-care technologies for sickle cell disease screening and monitoring.
Alapan Y, Fraiwan A, Kucukal E, Hasan M, Ung R, Kim M
Expert Rev Med Devices. 2016; 13(12):1073-1093.
PMID: 27785945
PMC: 5166583.
DOI: 10.1080/17434440.2016.1254038.
Dynamic deformability of sickle red blood cells in microphysiological flow.
Alapan Y, Matsuyama Y, Little J, Gurkan U
Technology (Singap World Sci). 2016; 4(2):71-79.
PMID: 27437432
PMC: 4947547.
DOI: 10.1142/S2339547816400045.
The Effect of Hydroxyurea Therapy in Bahraini Sickle Cell Disease Patients.
Shome D, Al Ajmi A, Radhi A, Mansoor E, Majed K
Indian J Hematol Blood Transfus. 2016; 32(1):104-9.
PMID: 26855516
PMC: 4733670.
DOI: 10.1007/s12288-015-0529-y.
A retrospective analysis of the cost of hospitalizations for sickle cell disease with crisis in England, 2010/11.
Pizzo E, Laverty A, Phekoo K, AlJuburi G, Green S, Bell D
J Public Health (Oxf). 2014; 37(3):529-39.
PMID: 24796312
PMC: 5896799.
DOI: 10.1093/pubmed/fdu026.
AKAP-dependent modulation of BCAM/Lu adhesion on normal and sickle cell disease RBCs revealed by force nanoscopy.
Maciaszek J, Andemariam B, Abiraman K, Lykotrafitis G
Biophys J. 2014; 106(6):1258-67.
PMID: 24655501
PMC: 3984978.
DOI: 10.1016/j.bpj.2014.02.001.
Patients with sickle cell disease taking hydroxyurea in the Hemocentro Regional de Montes Claros.
Santos F, Maia C
Rev Bras Hematol Hemoter. 2013; 33(2):105-9.
PMID: 23284256
PMC: 3520633.
DOI: 10.5581/1516-8484.20110029.
